AMLX
Amylyx Pharmaceuticals Inc
$21.63
0.85 (3.78%) Today
— up— down
Market Cap
$2.40B+157.2%
Revenue (TTM)
$0
$0Net Income (TTM)
$-159,257,437
$-159,257,437EPS (TTM)
-1.43
-1.43Shares Out
111.19M
111.19MOpen
$21.63
$21.63Previous Close
$22.48
$22.48Day Range
$21.30 – $22.39
$21.30 – $22.3952-Week Range
$7.63 – $24.60
$7.63 – $24.60Beta
-0.19
-0.19Earnings Date
Nov 4, 2026
Nov 4, 2026Volume
1.57M
1.57MAvg Volume
1.50M
1.50MAnalyst Rating
Buy
BuyExchange
NASDAQ NMS - GLOBAL MARKET
NASDAQ NMS - GLOBAL MARKETAbout AMLX
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.
Related
News
N/AN/AN/AN/AN/A
A $50 million hostage ransom funded al Qaeda's Mali offensive, UN says - Reuters
Reuters · 11h ago
UAE's ADNOC says one of its vessels came under attack while transiting Hormuz - Reuters
Reuters · 11h ago
Hormuz traffic slows further after US threatens more economic pressure on Iran - Reuters
Reuters · 12h ago
Trump says USS Abraham Lincoln deployment 'not nearly long enough' - Reuters
Reuters · 13h ago
Iran defiant on strait as Trump tells Americans to accept high gas prices - Reuters
Reuters · 14h ago